Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy

Bioconjugate Chemistry

Volumn 7, Issue 5, 1996, Pages 584-591

  Gedda, Lars ^a   Olsson, Pär ^a   Pontén, Jan ^b   Carlsson, Jörgen ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMS; CELLS; CYTOLOGY; TUMORS;

BORON ATOM; BORON NEUTRON CAPTURE THERAPY; BORON NEUTRONCAPTURE THERAPY; BREAST CANCER; EPIDERMAL GROWTH FACTOR RECEPTORS; EPIDERMAL GROWTH FACTORS; IN-VITRO; SQUAMOUS CARCINOMA; SUBSTITUTION RATES; VITRO STUDIES;

DEXTRAN;

EID: 0030250865     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc9600473     Document Type: Article

References (34)

1. Andersson, A., Holmberg, A., Carlsson, J., Carlsson, J., Pontén, J., and Westermark, B. (1991) Binding of epidermal growth factor-dextran conjugates to cultured glioma cells. Int. J. Cancer 47, 439-444.
2. 131I conjugates on the clonogenic survival of cultured glioma cells. J. Neuro-Oncol. 14, 213-223.
3. Barth, R. F., Soloway, A. H., and Fairchild, R. G. (1990) Boron neutron capture therapy of cancer. Cancer Res. 50, 1061-1070.
4. Bigner, D. D., Bigner, S. H., Pontén, J., Westermark, B., Mahaley, M. S., Jr., Ruoslahti, E., Herschman, H., Eng, L. F., and Wikstrand, C. J. (1981) Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J. Neuropathol. Exp. Neurol. 40, 201-229.
5. Bigner, S. H., Burger, P. C., Wong, A. J., Werner, M. H., Hamilton, S. R., Muilbaier, L. H., Vogelstein, B., and Bigner, D. D. (1988) Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J. Neuropath Exp. Neurol. 47, 191-205.
6. 131I-EGF on cultured human glioma cells. J. Neuro-Oncol. 9, 201-210.
7. Carlsson, J., Gedda, L., Grönvik, C., Hartman, T., Lindström, A., Lindström, P., Lundqvist, H., Lövqvist, A., Malmqvist, J., Olsson, P., Pontén, J., Sjöberg, S., and Westermark, B. (1994) Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. Int. J. Radiat. Oncol., Biol. Phys. 30, 105-115.
8. Cawley, D. B., Herschman, H. R., Gilliand, D. G., and Collier, R. J. (1980) Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-Diphtheria fragment A is nontoxic. Cell 22, 563-570.
9. Charlton, D. E. (1991) Energy deposition in small ellipsoidal volumes by high-LET particles: application to thermal neutron dosimetry. Int. J. Radiat. Biol. 59 (3), 827-842.
10. Collins, V. P., and James, C. D. (1993) Gene and chromosomal alterations associated with the development of human gliomas. FASEB J. 7, 926-930.
11. Fairchild, R. G., Kahl, S. B., Laster, B. H., Kalef-Ezra, J., and Popenoe, E. A. (1990) In vitro determination of uptake, retention, distribution, biological efficacy and toxicity of boronated compounds for neutron capture therapy; a comparison of porphyrines and sulfhydryl boron hydrides. Cancer Res. 50, 4860-4865.
12. Foster, R. L. (1975) Preparation and properties of a soluble trypsin-dextran conjugate. Experentia 31, 773-774.
13. 7Li reaction in cells and tissue and its implication for boron neutron capture therapy. Radiat. Res. 111, 14-25.
14. 125I-epidermal growth factor in Balb 3T3 cells. J. Biol. Chem. 255 (4), 1239-1241.
15. Hartman, T., and Carlsson, J. (1994) Radiation dose heterogeneous in receptor and antigen mediated boron neutron capture therapy. Radiother. Oncol. 31, 61-75.
16. Hawthorne, M. F. (1993) The role of chemistry in the development of boron neutron capture therapy of cancer. Angew. Chem., Int. Ed. Engl. 32, 950-984.
17. Holmberg, A., and Meurling, L. (1993) Preparation of sulfhydrylborane-dextran conjugates for boron neutron capture therapy. Bioconjugate Chem. 4 (6), 570-573.
18. Kohn, K., and Wilchek, M. (1984) The use of cyanogen bromide and other novel cyanylating agents for the activation of polysaccharide resins. Appl. Biochem. Biotechnol. 9, 285-305.
19. Lindström, P., Olsson, P., Malmqvist, J., Pettersson, J., Lemmen, P., Werner, B., Sjöberg, S., Olin, Å., and Carlsson, J. (1994) New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-1 and B-Et-11-OMe in cultured human glioma and mouse melanoma cells. Anti-Cancer Drugs 5, 43-52.
20. Locher, G. L. (1936) Biological effects and therapeutic possibilities of neutrons. Am. J. Roentgenol. Radium Ther. 36, 1-13.
21. 2 to soluble dextrans-I. Properties of conjugates and effects on plasma resistance in mice. Biochem. Pharmacol. 36 (1), 105-112.
22. Mendelsohn, J. (1988) Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Monoclonal Antibody Ther. 45, 147-160.
23. Olsson, P., Lindström, A., and Carlsson, J. (1994) Internalization and excretion of epidermal growth factor-dextran-associated radioactivity in cultured human squamous-carcinoma cells. Int. J. Cancer 56, 529-537.
24. Ozawa, S., Masakazu, U., Nobutoshi, A., Osahiko, A., Minoshima, S., and Shimizu, N. (1989) Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int. J Cancer 43, 152-157.
25. Reiter, Y., Brinkmann, U., Jung, S-H., Lee, B., Kasprzyk, P. G., King, C. R., and Pastan, I. (1994) Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem. 269 (28), 18327-18331.
26. Siegall, C. B., FitzGerald, D. J., and Pastan, I. (1990) Selective killing of tumor cells using EGF and TGFα-Pseudomonas exotoxin chimeric molecules. Semin. Cancer Biol. 1, 345-350.
27. Soloway, A. H., Hatanaka, H., and Davis, M. A. (1967) Penetration of brain and brain tumor VII. Tumor-binding sulfhydryl boron compounds. J. Med. Chem. 10, 714-717.
28. Stacey, F. W., and Harris, J. F., Jr. (1963) Formation of carbon-hetero atom bonds by free radical chain additions to carbon-carbon multiple bonds. In Org. React. (N.Y.) 13.
29. Vaughan, A. T. M., Anderson, P., Dykes, P. W., Chapman, C. E., and Bradwel, A. R. (1987) Limitations to the killings of tumors using radiolabelled antibodies. Br. J. Radiol. 60, 567-578.
30. Vollmar, A. M., Banker, D. E., Mendelsohn, J., and Herschman, H. R. (1987) Toxicity of ligand antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor. J. Cell. Physiol. 131, 418-425.
31. Werner, M. H., Humphrey, P. A., Bigner, D. D., and Bigner, S. H. (1988) Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. Acta Neuropathol. 77, 196-201.
32. Westermark, B., Magnusson, A., and Heldin, C-H. (1982) Effect of Epidermal growth factor on membrane motility and cell locomotion in cultures or human clonal glioma cells. J. Neurosci. Res. 8, 491-507.
33. 131I. Radiother. Oncol. 11, 133-142.
34. Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D., Pegram, C. N., Reist, C. J., Traweek, S. T., Wong, A. J., Zalutsky, M. R., and Bigner, D. D. (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140-3148.